2/7/2013 7:50:04 AM
Cambridge-based clinical stage biopharmaceutical firm Catabasis Pharmaceuticals has secured 8.7 million in a round of funding, according to company filings. In December 2011, Catabasis, which develops medicines to treat inflammatory and metabolic diseases, received another 8 million in a first round of financing, bringing its total amount raised to 47.6 million. The company counts SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures among its investors. Founded in 2008, the company said it has developed a pipeline of molecules that amplify the beneficial effects of omega-3 fatty acids to target the underlying causes of a variety of complex human diseases.
comments powered by